Cargando…

Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia

In lymphoid organs, nurse-like cells (NLCs) show properties of tumor-associated macrophages, playing a crucial role in chronic lymphocytic leukemia (CLL) cell survival. Ibrutinib, a potent inhibitor of Bruton's tyrosine kinase (BTK), is able to counteract pro-survival signals in CLL cells. Sinc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fiorcari, Stefania, Maffei, Rossana, Audrito, Valentina, Martinelli, Silvia, Hacken, Elisa ten, Zucchini, Patrizia, Grisendi, Giulia, Potenza, Leonardo, Luppi, Mario, Burger, Jan A., Deaglio, Silvia, Marasca, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323207/ https://www.ncbi.nlm.nih.gov/pubmed/27602755 http://dx.doi.org/10.18632/oncotarget.11782

Ejemplares similares

Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
por: Maffei, Rossana, et al.
Publicado: (2015)

Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia
por: Maffei, Rossana, et al.
Publicado: (2017)

Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection
por: Fiorcari, Stefania, et al.
Publicado: (2021)

Nurse-Like Cells and Chronic Lymphocytic Leukemia B Cells: A Mutualistic Crosstalk inside Tissue Microenvironments
por: Fiorcari, Stefania, et al.
Publicado: (2021)

Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia via Kynurenine/Aryl Hydrocarbon Receptor-Mediated MCL1 Modulation
por: Atene, Claudio Giacinto, et al.
Publicado: (2022)

BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia
por: Fiorcari, Stefania, et al.
Publicado: (2020)

Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ET(A) Receptor
por: Maffei, Rossana, et al.
Publicado: (2014)

Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1
por: Fiorcari, Stefania, et al.
Publicado: (2022)

Role of Notch2 pathway in mature B cell malignancies
por: Mesini, Nicolò, et al.
Publicado: (2023)

Effects of the BTN162b2 mRNA COVID‐19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia
por: Fiorcari, Stefania, et al.
Publicado: (2022)

The dynamic functions of IRF4 in B cell malignancies
por: Maffei, Rossana, et al.
Publicado: (2022)

Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges
por: Riva, Giovanni, et al.
Publicado: (2021)

BTK Inhibitors Impair Platelet-Mediated Antifungal Activity
por: Nasillo, Vincenzo, et al.
Publicado: (2022)

Pathogenetic Mechanisms of Hepatitis C Virus-Induced B-Cell Lymphomagenesis
por: Forghieri, Fabio, et al.
Publicado: (2012)

An 81-Year-Old Man with a 6-Year History of Chronic Lymphocytic Leukemia Presenting with Disease Flare Following Ibrutinib Discontinuation
por: Pozzi, Stefano, et al.
Publicado: (2022)

NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation
por: Audrito, Valentina, et al.
Publicado: (2020)

The Extracellular NADome Modulates Immune Responses
por: Audrito, Valentina, et al.
Publicado: (2021)

The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells
por: Fiorcari, Stefania, et al.
Publicado: (2013)

How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring
por: Talami, Annalisa, et al.
Publicado: (2021)

Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives
por: Forghieri, Fabio, et al.
Publicado: (2018)

NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer
por: Audrito, Valentina, et al.
Publicado: (2019)

Monocyte-to-macrophage switch reversibly impaired by Ibrutinib
por: Ferrarini, Isacco, et al.
Publicado: (2019)

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia
por: Tissino, Erika, et al.
Publicado: (2018)

Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
por: Bravaccini, Sara, et al.
Publicado: (2020)

Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report
por: Turcotte, Anna-Eve, et al.
Publicado: (2023)

Acute Myeloid Leukemia in Patients Living with HIV Infection: Several Questions, Fewer Answers
por: Forghieri, Fabio, et al.
Publicado: (2020)

Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia
por: Frezzato, Federica, et al.
Publicado: (2021)

Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia
por: Forghieri, Fabio, et al.
Publicado: (2021)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2019)

Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib
por: Koba, Yusuke, et al.
Publicado: (2023)

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
por: Landau, Dan A., et al.
Publicado: (2017)

Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?
por: Vaisitti, Tiziana, et al.
Publicado: (2018)

Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2019)

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
por: Kidoguchi, Keisuke, et al.
Publicado: (2021)

NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?
por: Forghieri, Fabio, et al.
Publicado: (2020)

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib
por: Jones, Jeffrey A., et al.
Publicado: (2017)

Molecular insights into the interaction between human nicotinamide phosphoribosyltransferase and Toll-like receptor 4
por: Gasparrini, Massimiliano, et al.
Publicado: (2022)

Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
por: Molica, Stefano, et al.
Publicado: (2016)

Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells
por: Holmes, Katie B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4ujvcuk629unfqjiuprnbvf9et